pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Wegovy
drug
save

Wegovy Pill

Marketedupdated 6mo ago
by Novo Nordisk Inc
Approved
annual revenue · 2024–2024peak $8.4B
2024: $8.4B2024$8.4B
community read0 votes

🐶 often sniffed alongside

top 8
  • drugOzempic168 co-mentions · 74 sources
  • drugWegovy168 co-mentions · 74 sources
  • tagApproval124 co-mentions · 44 sources
  • drugRybelsus94 co-mentions · 72 sources
  • drugsemaglutide94 co-mentions · 72 sources
  • tagRecall33 co-mentions · 27 sources
  • companyNovo Nordisk Inc22 co-mentions · 3 sources
  • tagSmall Molecule22 co-mentions · 18 sources

Protein drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 30 investigational indications.

indications

investigational
Obesity

all catalysts(2)

phase 1 completion · 1
Apr 30, 2026
phase 1 completion
7mo ago
Daewoong Therapeutics Inc — semaglutide (Phase I Trial Completion)
Wegovy Pill
→
phase 2 completion · 1
Apr 30, 2026
phase 2 completion
7mo ago
Gachon University Gil Medical Center — Wegovy (Phase II Trial Completion)
Wegovy Pill
→

Trials studying Wegovy Pill

  • phase3AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weightactive not recruitingn=985
  • phase1Evaluate the Safety and Tolerability of Multiple Doses of JMT206 Injection in Obese Participantsrecruitingn=90
  • phase3A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitusrecruitingn=1,200
  • phase4Semaglutide vs Sitagliptinactive not recruitingn=58
  • phase3A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesiaactive not recruitingn=152
  • phase3A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetesactive not recruitingn=1,500
  • phase3A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weightactive not recruitingn=212
  • phase1A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medicationnot yet recruitingn=60

Patent cliff

source: FDA Orange Book
first barrier falls
Mar 8, 2027
109 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (165)

  • Feb 17, 2041formulationUS 11318191
  • Feb 17, 2041formulationUS 11318191
  • Feb 17, 2041formulationUS 11318191
  • Feb 17, 2041formulationUS 11318191
  • Feb 17, 2041formulationUS 11318191
  • Feb 17, 2041formulationUS 11318191
  • May 13, 2040method-of-use (U-3861)US 11478533
  • May 13, 2040method-of-use (U-3861)US 11478533
  • May 13, 2040method-of-use (U-3861)US 11478533
  • May 13, 2040method-of-use (U-3861)US 11478533
  • May 13, 2040method-of-use (U-3861)US 11478533
  • Feb 1, 2039formulationUS 11833248
  • Feb 1, 2039formulationUS 11833248
  • Feb 1, 2039formulationUS 11833248
  • Feb 1, 2039formulationUS 11833248
  • Feb 1, 2039formulationUS 11833248
  • Feb 1, 2039formulationUS 11833248
  • Feb 1, 2039formulationUS 11833248
  • Feb 1, 2039formulationUS 12396953
  • Feb 1, 2039formulationUS 12396953
  • Feb 1, 2039formulationUS 12396953
  • Feb 1, 2039formulationUS 12396953
  • Feb 1, 2039formulationUS 12396953
  • Feb 1, 2039formulationUS 12396953
  • Feb 1, 2039formulationUS 12396953
  • Oct 10, 2038method-of-use (U-4418)US 12029779
  • Oct 10, 2038method-of-use (U-3162)US 12029779
  • Oct 10, 2038method-of-use (U-2628)US 12295988
  • Oct 10, 2038method-of-use (U-4418)US 12551536
  • Oct 10, 2038method-of-use (U-4418)US 12551536
  • Aug 24, 2038formulationUS 10888605
  • Aug 24, 2038formulationUS 10888605
  • Aug 24, 2038formulationUS 10888605
  • Aug 24, 2038formulationUS 10888605
  • Aug 24, 2038formulationUS 10888605
  • Aug 24, 2038formulationUS 10888605
  • Aug 24, 2038formulationUS 11752198
  • Aug 24, 2038formulationUS 11752198
  • Aug 24, 2038formulationUS 11752198
  • Aug 24, 2038formulationUS 11752198
  • Aug 24, 2038formulationUS 11752198
  • Aug 24, 2038formulationUS 11752198
  • Aug 24, 2038formulationUS 12214017
  • Aug 24, 2038formulationUS 12214017
  • Aug 24, 2038formulationUS 12214017
  • Aug 24, 2038formulationUS 12214017
  • Aug 24, 2038formulationUS 12214017
  • Aug 24, 2038formulationUS 12214017
  • Apr 28, 2037method-of-use (U-4443)US 12569543
  • Apr 28, 2037method-of-use (U-4443)US 12569543
  • Apr 28, 2037method-of-use (U-4443)US 12569543
  • Apr 28, 2037method-of-use (U-4443)US 12569543
  • Apr 28, 2037method-of-use (U-4443)US 12569543
  • Apr 28, 2037method-of-use (U-4443)US 12569543
  • Apr 28, 2037method-of-use (U-4446)US 12569543
  • Apr 28, 2037method-of-use (U-4446)US 12569543
  • Apr 28, 2037method-of-use (U-4446)US 12569543
  • May 2, 2034method-of-use (U-4389)US 10278923
  • May 2, 2034method-of-use (U-4389)US 10278923
  • May 2, 2034method-of-use (U-4389)US 10278923
  • May 2, 2034method-of-use (U-4389)US 10278923
  • May 2, 2034method-of-use (U-2628)US 10278923
  • May 2, 2034method-of-use (U-2628)US 10278923
  • May 2, 2034method-of-use (U-2628)US 10278923
  • May 2, 2034compositionUS 10278923
  • May 2, 2034compositionUS 10278923
  • May 2, 2034compositionUS 10278923
  • May 2, 2034method-of-use (U-4388)US 12239739
  • May 2, 2034compositionUS 12239739
  • May 2, 2034compositionUS 12239739
  • May 2, 2034compositionUS 12239739
  • May 2, 2034compositionUS 12239739
  • May 2, 2034compositionUS 12239739
  • May 2, 2034compositionUS 12239739
  • May 2, 2034method-of-use (U-4388)US 12239739
  • May 2, 2034method-of-use (U-4388)US 12239739
  • May 2, 2034method-of-use (U-4388)US 12239739
  • May 2, 2034method-of-use (U-2628)US 12514822
  • May 2, 2034method-of-use (U-2628)US 12514822
  • May 2, 2034method-of-use (U-2628)US 12514822
  • May 2, 2034method-of-use (U-2628)US 12514822
  • May 2, 2034method-of-use (U-2628)US 12514822
  • May 2, 2034method-of-use (U-2628)US 12514822
  • Jun 21, 2033formulationUS 10335462
  • Jun 21, 2033method-of-use (U-2580)US 10335462
  • Jun 21, 2033method-of-use (U-2580)US 10335462
  • Jun 21, 2033method-of-use (U-3161)US 9764003
  • Jun 21, 2033method-of-use (U-3161)US 9764003
  • Jun 21, 2033method-of-use (U-3161)US 9764003
  • Jun 21, 2033method-of-use (U-3161)US 9764003
  • Jun 21, 2033method-of-use (U-4418)US 9764003
  • Jun 21, 2033method-of-use (U-3161)US 9764003
  • Mar 15, 2033formulationUS 10933120
  • Mar 15, 2033formulationUS 10933120
  • Mar 15, 2033formulationUS 10933120
  • Mar 15, 2033formulationUS 11759501
  • Mar 15, 2033formulationUS 11759501
  • Mar 15, 2033formulationUS 11759501
  • Mar 15, 2033formulationUS 11759502
  • Mar 15, 2033formulationUS 11759502
  • Mar 15, 2033formulationUS 11759502
  • Mar 15, 2033formulationUS 11759503
  • Mar 15, 2033formulationUS 11759503
  • Mar 15, 2033formulationUS 11759503
  • Dec 16, 2031formulationUS 10086047
  • Dec 16, 2031formulationUS 10086047
  • Dec 16, 2031formulationUS 10086047
  • Dec 16, 2031formulationUS 10960052
  • Dec 16, 2031formulationUS 10960052
  • Dec 16, 2031formulationUS 10960052
  • Dec 16, 2031compositionUS 11382957
  • Dec 16, 2031formulationUS 11382957
  • Dec 16, 2031formulationUS 11382957
  • Dec 16, 2031formulationUS 11382957
  • Dec 16, 2031compositionUS 11382957
  • Dec 16, 2031formulationUS 11382957
  • Dec 16, 2031compositionUS 11382957
  • Dec 16, 2031formulationUS 11382957
  • Dec 16, 2031formulationUS 11382957
  • Dec 16, 2031formulationUS 11382957
  • Dec 16, 2031formulationUS 9278123
  • Dec 16, 2031compositionUS 9278123
  • Dec 16, 2031formulationUS 9278123
  • Dec 16, 2031formulationUS 9278123
  • Dec 16, 2031formulationUS 9278123
  • Dec 16, 2031formulationUS 9278123
  • Dec 5, 2031compositionUS 8129343
  • Dec 5, 2031compositionUS 8129343
  • Dec 5, 2031compositionUS 8129343
  • Dec 5, 2031compositionUS 8129343
  • Dec 5, 2031compositionUS 8129343
  • Dec 5, 2031compositionUS 8129343
  • Dec 5, 2031compositionUS 8129343
  • Dec 5, 2031compositionUS 8129343
  • Dec 5, 2031compositionUS 8129343
  • Dec 5, 2031compositionUS 8129343
  • Dec 5, 2031compositionUS 8129343
  • Dec 5, 2031compositionUS 8129343
  • Dec 5, 2031compositionUS 8129343
  • Dec 5, 2031compositionUS 8129343
  • Dec 5, 2031compositionUS 8129343
  • Dec 5, 2031compositionUS 8129343
  • Dec 5, 2031compositionUS 8129343
  • Dec 5, 2031compositionUS 8129343
  • Dec 5, 2031compositionUS 8129343
  • Dec 5, 2031compositionUS 8129343
  • Mar 20, 2026compositionUS 8536122
  • Mar 20, 2026compositionUS 8536122
  • Mar 20, 2026compositionUS 8536122
  • Mar 20, 2026compositionUS 8536122
  • Mar 20, 2026compositionUS 8536122
  • Mar 20, 2026compositionUS 8536122
  • Mar 20, 2026compositionUS 8536122
  • Mar 20, 2026compositionUS 8536122
  • Mar 20, 2026compositionUS 8536122
  • Mar 20, 2026compositionUS 8536122
  • Mar 20, 2026compositionUS 8536122
  • Mar 20, 2026compositionUS 8536122
  • Mar 20, 2026compositionUS 8536122
  • Mar 20, 2026compositionUS 8536122
  • Mar 20, 2026compositionUS 8536122
  • Mar 20, 2026compositionUS 8536122
  • Mar 20, 2026compositionUS 8536122
  • Mar 20, 2026compositionUS 8536122
  • Mar 20, 2026compositionUS 8536122

FDA exclusivities (29)

  • Dec 22, 2028NPNP2.1y
  • Dec 22, 2028NPNP2.1y
  • Dec 22, 2028NPNP2.1y
  • Dec 22, 2028NPNP2.1y
  • Oct 17, 2028I-976Indication (3y)1.9y
  • Oct 17, 2028I-976Indication (3y)1.9y
  • Oct 17, 2028I-976Indication (3y)1.9y
  • Oct 17, 2028I-976Indication (3y)1.9y
  • Oct 17, 2028I-976Indication (3y)1.9y
  • Oct 17, 2028I-976Indication (3y)1.9y
  • Aug 15, 2028I-973Indication (3y)1.7y
  • Aug 15, 2028I-973Indication (3y)1.7y
  • Aug 15, 2028I-973Indication (3y)1.7y
  • Aug 15, 2028I-973Indication (3y)1.7y
  • Aug 15, 2028I-973Indication (3y)1.7y
  • Jan 28, 2028I-961Indication (3y)1.2y
  • Jan 28, 2028I-961Indication (3y)1.2y
  • Jan 28, 2028I-961Indication (3y)1.2y
  • Jan 28, 2028I-961Indication (3y)1.2y
  • Mar 8, 2027I-935Indication (3y)109d
  • Mar 8, 2027I-935Indication (3y)109d
  • Mar 8, 2027I-935Indication (3y)109d
  • Mar 8, 2027I-935Indication (3y)109d
  • Mar 8, 2027I-935Indication (3y)109d
  • Mar 8, 2027I-935Indication (3y)109d
  • Mar 8, 2027I-935Indication (3y)109d
  • Mar 8, 2027I-935Indication (3y)109d
  • Mar 8, 2027I-935Indication (3y)109d
  • Jul 21, 2026D-190New Indication (3y)

News(10)

  • ‘Selling and marketing snake oil’: The debate over compounded GLP-1s
    Proponents of compounding argue it increases access, lowers prices and helps patients who may need individualized versions of a drug. But there are serious concerns, experts said at the HLTH confer…
    biopharma_dive · 10h ago
  • Novo’s consumer push gains momentum with Wegovy pill, CagriSema on deck
    LAS VEGAS — When Ed Cinca returned to Novo after four years away, he barely recognized the place. “I think the building’s the same, but that’s about it,” Cinca, Novo’s senior vice president of mark…
    endpoints · 10h ago
  • STAT+: Pharmalittle: We’re reading about a Roche breast cancer pill, obesity drugs in children, and more
    The FDA approved a breast cancer drug from Roche, teeing up the launch of what the company has said could become its top-selling product
    stat · 1d ago
  • STAT+: Newer GLP-1 drugs to combat obesity may be the next global battleground over access to medicines, expert warns
    How obesity medications may become the next big battleground over access to medicines in lower-income countries.
    stat · 2d ago
  • Novo’s CagriSema drives more than 20% weight loss at lower doses
    As Novo awaits an FDA decision for its next-gen obesity asset, the company has presented more data at ObesityWeek that could help buoy sentiment on the amylin/GLP-1 combination that disappointed in…
    biospace · 2d ago
  • Biopharma pushes beyond GLP-1s, weight loss at ObesityWeek 2026
    ObesityWeek 2026, which kicks off on Saturday, will spotlight presentations on the ascendant amylin pathway, as well as therapies looking to improve the quality of weight loss and patients’ persist…
    biospace · 5d ago
  • Blackstone bets $1.5B on Pfizer’s obesity drug
    The deal will support a sprawling Phase 3 program for a monthly GLP-1 shot Pfizer acquired by winning a bidding war for the drug’s previous owner, Metsera.
    biopharma_dive · 6d ago
  • Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked November
    Novartis confirms that nine patients treated with its spinal muscular atrophy gene therapy Zolgensma have developed tumors; the FDA orders GLP-1 drugmakers to add a warning to their labels about th…
    biospace · 7d ago
  • STAT+: Pharmalittle: We’re reading about an approval for novel drug for strokes, a warning for GLP-1 drugs, and more
    The FDA approved a novel drug to reduce recurrence of stroke, the agency is warning that GLP-1s carry a potential risk for an eye condition, and more pharma news of…
    stat · 8d ago
  • Altimmune gears up for FDA meeting on pivotal Phase 3 trial in alcohol use disorder
    Having linked its glucagon/GLP-1 candidate to a significant reduction in heavy drinking days, Altimmune is preparing to speak to the FDA in December about the design of a Phase 3 program.
    biospace · 8d ago
view all news mentions →
brand
Wegovy
generic
semaglutide
MOA
Glucagon-like peptide 1 receptor agonist
indication
type 2 diabetes, cardiovascular risk reduction
phase
marketed
approved
2017-12-05
Data sources
openFDA · ClinicalTrials.gov
last refreshed 2h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?